Revenue: As of FY2025 Q3, the actual value is USD 10.45 M, beating the estimate of USD 10.23 M.EPS: As of FY2025 Q3, the actual value is USD -0.08, beating the estimate of USD -0.094.EBIT: As of FY2025 Q3, the actual value is USD -3.827 M.<h3>Segment Revenue</h3><ul><li>Lab Essentials: Revenue for the three months ended September 30, 2025, was $8.3 million, an increase of $1.1 million or 16.0% compared to $7.2 million for the same period in 2024.</li><li>Clinical Solutions: Revenue for the three months ended September 30, 2025, was $1.7 million, a decrease of $0.3 million or 13.1% compared to $2.0 million for the same period in 2024.</li><li>Other: Revenue for the three months ended September 30, 2025, was $0.4 million, a decrease of $0.01 million or 2.4% compared to $0.45 million for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended September 30, 2025, net loss was $4.3 million, compared to $7.6 million for the same period in 2024.</li><li>Gross Profit: Gross profit for the three months ended September 30, 2025, was $3.2 million, compared to $0.09 million for the same period in 2024, with a gross profit percentage of 30.7% compared to 0.9% in 2024.</li><li>Operating Loss: Operating loss for the three months ended September 30, 2025, was $4.0 million, compared to $7.4 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $8.2 million, compared to $11.5 million for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: For the nine months ended September 30, 2025, net cash provided by investing activities was $7.5 million, compared to net cash used of $25.9 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $0.2 million, compared to $15.0 million for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to invest in processes and infrastructure to improve operating efficiency and expand capacity at its facilities, including the ramp-up of new manufacturing, warehouse, and distribution facilities.</li><li>Non-Core Business: The company is monitoring economic uncertainty and inflation, which may impact customer demand and costs.</li><li>Priority: The company aims to meet minimum net revenue requirements of $39.0 million for the twelve months ending December 31, 2025, and maintain a minimum cash requirement of $8.0 million.</li></ul>

Alpha Teknova | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 10.45 M